RxDoctor Payments Data

Lan Luo

Neurology · New York, NYNPI 1053603522

Payments from drug & device makers

$34,328in general payments, 2019–2025

Across 69 payments — averaging $497.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$20K
  • Tanabe Pharma America, Inc.$10K
  • Boston Scientific$3K
  • Medtronic$1K
  • Neurocrine Biosciences, Inc.$166
  • Bristol Myers Squibb$27
  • plus $23 from 1 others

What the payments were for

  • Consulting fees$9,22564%
  • Travel & lodging$2,88320%
  • Food & beverage$2,32416%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,328 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$66,553
Medicare patients
201
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate29$261,346
RytaryCarbidopa/Levodopa49$80,010
GocovriAmantadine Hcl15$27,143
Carbidopa-LevodopaCarbidopa/Levodopa455$19,104
MyrbetriqMirabegron17$14,645
Entacapone33$10,669
Selegiline Hcl79$9,289
Carbidopa-Levodopa ErCarbidopa/Levodopa124$8,255
RivastigmineRivastigmine Tartrate105$7,883
AmantadineAmantadine Hcl68$7,026
Carbidopa13$4,164
Rivastigmine16$3,797
Rasagiline Mesylate22$3,455
Baclofen30$2,215
Midodrine Hcl33$2,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$166$261,34629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →